Clinical Trial Detail

NCT ID NCT03141177
Title A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

renal cell carcinoma

clear cell renal cell carcinoma

Therapies

Cabozantinib + Ipilimumab + Nivolumab

Sunitinib

Cabozantinib + Nivolumab

Age Groups: adult senior

No variant requirements are available.